Transax International

H-CYTE, Inc., formerly known as Transax International Limited, is a biopharmaceutical and medical technology company specializing in regenerative medicine for chronic respiratory conditions. The company focuses on the development and delivery of autologous cellular therapies, which utilize a patient's own biologics to treat inflammatory lung diseases such as Chronic Obstructive Pulmonary Disease (COPD). Historically, the company was known for its Transax needle-free injection technology before pivoting its business model through a reverse merger with H-CYTE in 2018. Currently, the company operates by providing specialized treatment protocols and partnering with clinical providers to improve patient outcomes in the pulmonary space. H-CYTE is headquartered in Tampa, Florida, and its shares have historically been traded on the OTC markets. The company's approach combines medical device technology with biologics to offer non-invasive options for patients with compromised lung function.